|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 446.78 USD | +0.64% |
|
+1.84% | -1.45% |
| 04-09 | Evercore ISI Adjusts Vertex Pharmaceuticals PT to $535 From $530, Maintains Outperform Rating | MT |
| 04-07 | Halozyme Unit Enters License Deal With Vertex Pharmaceuticals for Hypercon Technology | MT |
| Capitalization | 114B 97.14B 89.79B 84.66B 157B 10,501B 161B 1,060B 413B 5,065B 426B 417B 18,088B | P/E ratio 2026 * |
25.5x | P/E ratio 2027 * | 22.3x |
|---|---|---|---|---|---|
| Enterprise value | 100B 85.7B 79.22B 74.69B 139B 9,264B 142B 935B 365B 4,468B 376B 368B 15,957B | EV / Sales 2026 * |
7.69x | EV / Sales 2027 * | 6.67x |
| Free-Float |
99.04% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Vertex Pharmaceuticals Incorporated
| 1 day | +0.64% | ||
| 1 week | +1.84% | ||
| Current month | +0.05% | ||
| 1 month | -3.06% | ||
| 3 months | -3.68% | ||
| 6 months | +7.69% | ||
| Current year | -1.45% |
| 1 week | 425.26 |  | 447 |
| 1 month | 425.26 | | 499.5 |
| Current year | 425.26 | | 507.92 |
| 1 year | 362.5 | | 510.77 |
| 3 years | 316.43 | | 519.88 |
| 5 years | 176.36 | | 519.88 |
| 10 years | 71.46 | | 519.88 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 53 | 31/03/2020 | |
Charles Wagner
DFI | Director of Finance/CFO | 58 | 09/04/2019 |
Mark Bunnage
CTO | Chief Tech/Sci/R&D Officer | - | 30/06/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Bruce Sachs
BRD | Director/Board Member | 66 | 31/12/1997 |
Jeffrey Leiden
CHM | Chairman | 70 | 30/04/2012 |
Sangeeta Bhatia
BRD | Director/Board Member | 57 | 17/06/2015 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.64% | +1.84% | -7.36% | +38.90% | 114B | |
| +0.20% | +2.10% | +26.73% | +159.36% | 855B | |
| +0.00% | -0.71% | +59.84% | +46.12% | 581B | |
| +0.38% | +1.70% | +18.10% | +31.48% | 376B | |
| +0.91% | 0.00% | +35.09% | +15.85% | 320B | |
| +0.94% | +2.96% | +53.73% | +32.42% | 318B | |
| -0.41% | +1.50% | +49.77% | +9.21% | 303B | |
| +1.05% | +2.84% | +45.44% | +41.85% | 295B | |
| +1.66% | +2.20% | +22.16% | +40.38% | 192B | |
| +0.39% | +1.70% | +35.00% | +70.43% | 176B | |
| Average | +0.51% | +0.70% | +33.85% | +48.60% | 353B | |
| Weighted average by Cap. | +0.33% | +0.82% | +37.06% | +65.14% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 13.03B 11.14B 10.3B 9.71B 18.02B 1,204B 18.43B 122B 47.4B 581B 48.91B 47.87B 2,074B | 14.35B 12.27B 11.34B 10.69B 19.84B 1,326B 20.3B 134B 52.19B 640B 53.86B 52.72B 2,284B |
| Net income | 4.49B 3.84B 3.55B 3.34B 6.21B 415B 6.35B 41.88B 16.33B 200B 16.85B 16.49B 715B | 5.17B 4.42B 4.08B 3.85B 7.15B 478B 7.31B 48.22B 18.8B 230B 19.4B 18.99B 823B |
| Net Debt | -13.39B -11.44B -10.58B -9.97B -18.51B -1,237B -18.93B -125B -48.68B -597B -50.24B -49.17B -2,131B | -17.93B -15.33B -14.17B -13.36B -24.79B -1,657B -25.36B -167B -65.21B -799B -67.29B -65.86B -2,854B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 09/04/26 | 446.78 $ | +0.64% | 1,040,964 |
| 08/04/26 | 443.92 $ | +2.79% | 1,279,267 |
| 07/04/26 | 431.86 $ | -0.56% | 1,029,161 |
| 06/04/26 | 434.30 $ | -1.01% | 948,862 |
| 02/04/26 | 438.71 $ | -1.91% | 1,244,992 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- VRTX Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition